Stephen Elledge's Har­vard lab again proves fruit­ful with the launch of high-through­put an­ti­body start­up

Af­ter work­ing with es­teemed Har­vard pro­fes­sor Stephen Elledge to launch TCR-fo­cused TScan Ther­a­peu­tics three years ago, the Long­wood Fund ap­proached the sci­en­tist last spring about spin­ning out more of his work.

To­geth­er, they launched a Cam­bridge, MA-based start­up in De­cem­ber called Im­muneID, which us­es Elledge’s plat­form to iden­ti­fy and tar­get the an­ti­body in­ter­ac­tions that dri­ve im­mune dis­eases, like se­vere al­ler­gies. And on Wednes­day morn­ing, the com­pa­ny un­veiled a $50 mil­lion Se­ries A round, bring­ing its to­tal raise to over $70 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER